GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Odonate Inc (OTCPK:ODTC) » Definitions » Intrinsic Value: Projected FCF

Odonate (Odonate) Intrinsic Value: Projected FCF : $0.00 (As of Jun. 10, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Odonate Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-06-10), Odonate's Intrinsic Value: Projected FCF is $0.00. The stock price of Odonate is $17100.00. Therefore, Odonate's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Odonate's Intrinsic Value: Projected FCF or its related term are showing as below:

ODTC's Price-to-Projected-FCF is not ranked *
in the Diversified Financial Services industry.
Industry Median: 0.885
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Odonate Intrinsic Value: Projected FCF Historical Data

The historical data trend for Odonate's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Odonate Intrinsic Value: Projected FCF Chart

Odonate Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial - - - - -

Odonate Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Odonate's Intrinsic Value: Projected FCF

For the Shell Companies subindustry, Odonate's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Odonate's Price-to-Projected-FCF Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Odonate's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Odonate's Price-to-Projected-FCF falls into.



Odonate Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



Odonate  (OTCPK:ODTC) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Odonate's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=17100.00/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Odonate Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Odonate's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Odonate (Odonate) Business Description

Traded in Other Exchanges
N/A
Address
3 East 28th Street, 10th Floor, New York, NY, USA, 10016
Odonate Inc is a Shell company.
Executives
Ecor1 Capital, Llc 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Boxer Capital, Llc director, 10 percent owner 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Kevin C Tang director, 10 percent owner, officer: Chief Executive Officer 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Aaron I. Davis director, 10 percent owner 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Craig A Johnson director C/O PURE BIOSCIENCE, 1725 GILLESPIE WAY, EL CAJON CA 92020
Jeff L Vacirca director 4747 EXECUTIVE DRIVE, SUITE 510, SAN DIEGO CA 92121
Laura L. Johnson director C/O LA JOLLA PHARMACEUTICAL COMPANY, LA JOLLA VILLAGE DRIVE, SUITE 1070, SAN DIEGO CA 92122
Michael S Hearne officer: Chief Financial Officer 4747 EXECUTIVE DRIVE SUITE 210 SAN DIEGO CA 92121
Joseph P O'connell officer: Chief Medical Officer 4747 EXECUTIVE DRIVE SUITE 210 SAN DIEGO CA 92121
Boxer Asset Management Inc. 10 percent owner CAY HOUSE, EP TAYLOR DRIVE N7776, LYFORD CAY, NEW PROVIDENCE C5 00000
Robert Rosen director C/O HERON THERAPEUTICS, INC, 4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO CA 92121
Joseph Lewis 10 percent owner PO BOX N7776, LYFORD BAHAMAS
Tang Capital Management Llc 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Partners Lp 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
John G Lemkey officer: Chief Financial Officer 4747 EXECUTIVE DRIVE SUITE 210 SAN DIEGO CA 92121

Odonate (Odonate) Headlines

From GuruFocus

Odonate Announces Expected Delisting of Its Stock

By Business Wire Business Wire 01-07-2022